Drug Trial Radar · NCT00471094
Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
Last checked: Nov 19, 2026Latest source record: Feb 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
831
Actual
Start
May 2007
Primary completion
Oct 2007
Study completion Oct 2007
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- May 9, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of 8 weeks of daily treatment with Ilaprazole (5, 20 and 40 mg), once daily (QD), compared to lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
Conditions
- Esophagitis
Interventions
IlaprazoleDrug
Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
IlaprazoleDrug
Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
IlaprazoleDrug
Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
LansoprazoleDrug
Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The crude healing rate of Erosive Esophagitis at week 4 of treatment as assessed by endoscopy.Time frame: Week 4
Locations
94 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Hueytown, Alabama
Site not named
Huntsville, Alabama
Site not named
Chandler, Arizona
Site not named
Phoenix, Arizona
Site not named
Tempe, Arizona
Site not named
Tucson, Arizona
Site not named
Sherwood, Arkansas
Site not named
Anaheim, California
Site not named
Cypress, California
Site not named
Encinitas, California
Site not named
Garden Grove, California
Site not named
Irvine, California
Site not named
Lancaster, California
Site not named
Mission Hills, California
Site not named
Oakland, California
Site not named
Orange, California
Site not named
Pasadena, California
Site not named
San Diego, California
Site not named
West Covina, California
Site not named
Colorado Springs, Colorado
Site not named
Longmont, Colorado
Site not named
Pueblo, Colorado
Site not named
Bristol, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Longwood, Florida
Site not named
Miami, Florida
Site not named
New Smyrna Beach, Florida
Site not named
Pembroke Pines, Florida
Site not named
Tampa, Florida
Site not named
Zephyrhills, Florida
Site not named
Atlanta, Georgia
Site not named
Conyers, Georgia
Site not named
Newnan, Georgia
Site not named
Tucker, Georgia
Site not named
Boise, Idaho
Site not named
Moline, Illinois
Site not named
Rockford, Illinois
Site not named
Clive, Iowa
Site not named
Davenport, Iowa
Site not named
Dubuque, Iowa
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.